PMID: 3757160Jan 1, 1986Paper

A phase II study of human rDNA alpha-2 interferon in patients with low grade non-Hodgkin's lymphoma

Cancer Chemotherapy and Pharmacology
J WagstaffD Crowther

Abstract

Thirty-five patients with a diagnosis of non-Hodgkin's lymphoma of low histological grade were treated with 2 X 10(6)/m2 of human rDNA alpha 2 IFN-a2 by subcutaneous injection. Treatment was continued until progressive disease was documented or one year of therapy had been given. None of the patients had to stop treatment because of toxicity and no treatment delays or suspensions of therapy were necessary as a consequence of myelosuppression. Thirty four patients were evaluable and seventeen (50%) obtained an objective response (2 CR, 15 PR) with a median duration of eleven months. Sixteen patients were untreated prior to receiving interferon but were felt to need some form of therapy rather than be suitable for a watch policy. Eleven of these patients responded (69%) with 95% confidence limits lying between 41% and 89%. No other pretreatment factors appeared to affect the likelihood of response. Single agent IFN-alpha 2 has significant activity in the low grade non-Hodgkin's lymphomata and warrants further investigation in this disease.

References

Feb 1, 1979·International Journal of Radiation Oncology, Biology, Physics·T L TharW D Noyes
Jan 1, 1978·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·I GresserM Tovey
Oct 1, 1973·Journal of the National Cancer Institute·M A Chirigos, J W Pearson
Nov 1, 1984·The New England Journal of Medicine·K A FoonJ Zeffren
Dec 6, 1984·The New England Journal of Medicine·S J Horning, S A Rosenberg

❮ Previous
Next ❯

Citations

Jan 1, 1989·Journal of Cancer Research and Clinical Oncology·F PorzsoltH Schönenberger
Nov 5, 1992·The New England Journal of Medicine·R V SmalleyE C Borden
Nov 1, 1991·British Journal of Haematology·A Z Rohatiner, T A Lister
May 1, 1990·Journal of Clinical Pathology·M BhavnaniJ A Yin
Feb 28, 2007·Leukemia & Lymphoma·Koen van Besien, Harry Schouten
Jan 1, 1992·Clinical Immunology and Immunopathology·E C Borden
Feb 3, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A Z S RohatinerT A Lister
Mar 1, 1987·Baillière's Clinical Haematology·T Takvorian, G Canellos
May 1, 1990·Journal of Clinical Pathology·T Karttunen, S Niemelä
Dec 30, 2015·The Cochrane Database of Systematic Reviews·Chris CoppinTimothy J Wilt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.